- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03696433
Visualizing Vascular Mechanisms of Salt Sensitivity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypertension is a major cause of heart disease, heart failure, and stroke. Hypertension, or high blood pressure, affects people differently and is related to the body's ability to maintain healthy circulation of salt. Some individuals may be affected by salt sensitive blood pressure (SSBP), when their blood pressure changes in response to dietary salt load. SSBP is a prevalent, independent risk factor for developing cardiovascular disease that preferentially affects black individuals. Current methods to assess SSBP require dietary salt loading over the course of days to weeks, and measurement of blood pressure following high salt diet and low salt diet. Such lengthy protocols are not feasible in a clinical setting to evaluate this risk factor for cardiovascular disease, and more importantly, these procedures provide incomplete information about mechanisms of salt sensitivity.
Our knowledge regarding salt handling in the body is limited. While renal dysfunction is partly responsible for SSBP, recent research points to the role of lymphatic vascular clearance in regulating tissue salt storage and blood pressure control. To better understand these mechanisms in vivo, we have recently developed a noninvasive magnetic resonance (MR) lymphangiography method sensitive to lymphatic vasculature, and applied standardized MR protocols for measuring tissue sodium and fat storage in adults with impaired lymphatic clearance. We found evidence of lymph stasis and tissue salt deposition that correlated with local subcutaneous fat volume. Here, we will test whether similar lymphatic pathways are impaired in persons with SSBP, leading to tissue salt and fat storage, in comparison to the involvement of renal dysfunction in SSBP tissue profiles.
The aims of this study are to improve our understanding of vascular mechanisms of human salt storage, and to provide standardized radiologic biomarkers sensitive to the SSBP phenotype. This study will test the primary hypothesis that the SSBP response is correlated with baseline tissue sodium storage, and elevated in persons with salt sensitivity. Secondary hypotheses will address whether the SSBP response is related to fat storage, lymphatic vascular function, renal vascular function, and impaired target organ responses to salt loading, including decreased urinary sodium excretion, and less suppression of plasma renin and serum aldosterone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Karlis Draulis, BS
- Phone Number: 615-875-6028
- Email: karlis.j.draulis@vumc.org
Study Contact Backup
- Name: Cassandra Reynolds, BS, CCRC
- Phone Number: 615-875-9854
- Email: cassandra.f.reynolds@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Identification as black race
- Age between 18 and 55 years
- Body mass index between 25 and <35 kg/m2
- Normotensive or pre-hypertensive
- Willing to adhere to study diets
- Able to provide informed consent and communicate with study personnel
Exclusion Criteria:
- Prevalent cardiovascular disease or use of medications for cardiovascular disease
- Current or prior history of hypertension or use of blood pressure lowering medications
- Current or prior history of diabetes mellitus or use of anti-diabetic medications
- Prevalent renal disease (eGFR < 60 ml/min/1.73m2), abnormal serum sodium or potassium
- Current or prior smoker
- Current pregnancy, or use of hormone replacement therapy or oral contraceptive
- Current steroid use
- Contraindications to MRI
- Active infection or open wounds on the top of the feet or hands
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low- then high-salt diet
10 subjects will be enrolled and each will undergo study procedures at 4 separate visits.
Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets.
After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet.
Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
|
The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
|
Experimental: High- then low-salt diet
10 subjects will be enrolled and each will undergo study procedures at 4 separate visits.
Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets.
After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet.
Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
|
The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Salt-sensitive blood pressure after low salt diet
Time Frame: Following completion of all dietary supplements and washout, in no less than 21 days.
|
Measured as the difference in mean arterial pressure following high-salt diet compared to low-salt diet
|
Following completion of all dietary supplements and washout, in no less than 21 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tissue sodium content of the legs
Time Frame: At baseline
|
Measured by sodium MRI
|
At baseline
|
Fat fraction of the legs
Time Frame: At baseline
|
Measured by conventional MRI, in units of fat/water volume ratio
|
At baseline
|
Kidney blood perfusion rate
Time Frame: At baseline
|
Measured by conventional noninvasive MRI
|
At baseline
|
Lymphatic stasis of the legs
Time Frame: At baseline
|
Measured by noninvasive MR lymphangiography
|
At baseline
|
Urinary sodium excretion
Time Frame: At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Measured from 24-hour urine collection
|
At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Plasma renin
Time Frame: At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Physiological parameter
|
At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Serum aldosterone
Time Frame: At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Physiological parameter
|
At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Rachelle Crescenzi, PhD, Department of Radiology, Vanderbilt University Medical Center
Publications and helpful links
General Publications
- Crescenzi R, Marton A, Donahue PMC, Mahany HB, Lants SK, Wang P, Beckman JA, Donahue MJ, Titze J. Tissue Sodium Content is Elevated in the Skin and Subcutaneous Adipose Tissue in Women with Lipedema. Obesity (Silver Spring). 2018 Feb;26(2):310-317. doi: 10.1002/oby.22090. Epub 2017 Dec 27.
- Crescenzi R, Donahue PMC, Hartley KG, Desai AA, Scott AO, Braxton V, Mahany H, Lants SK, Donahue MJ. Lymphedema evaluation using noninvasive 3T MR lymphangiography. J Magn Reson Imaging. 2017 Nov;46(5):1349-1360. doi: 10.1002/jmri.25670. Epub 2017 Feb 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 181610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Low-salt diet
-
University of Southern DenmarkOdense University Hospital; Beckett Foundation; Danish Diabetes AcademyCompleted
-
Brigham and Women's HospitalTerminatedAutoimmunity | Sodium Chloride | Salt Intake | Th17 Helper Immune CellsUnited States
-
University of MichiganRenal Research InstituteCompletedKidney DiseaseUnited States
-
Vanderbilt UniversityCompleted
-
Aga Khan UniversityWellcome TrustUnknown
-
Wolfson Medical CenterUnknown
-
Hospital Clínico Universitario de ValladolidUnknown
-
Josip Juraj Strossmayer University of OsijekRecruitingPsoriasis VulgarisCroatia
-
Bangkok Metropolitan Administration Medical College...Science research and innovationCompleted
-
University Hospital, GenevaCompleted